Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: JAKAFI

« Back to Dashboard

Jakafi is a drug marketed by Incyte Corp and is included in one NDA. It is available from one supplier. There are five patents protecting this drug.

The generic ingredient in JAKAFI is ruxolitinib phosphate. One supplier is listed for this compound. Additional details are available on the ruxolitinib phosphate profile page.

Summary for Tradename: JAKAFI

Suppliers: see list1

Pharmacology for Tradename: JAKAFI

Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors

Clinical Trials for: JAKAFI

Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Status: Recruiting Condition: Leukemia

Study of Ruxolitinib Plus Decitabine in Patients With Acute Myeloid Leukemia (AML)
Status: Not yet recruiting Condition: Leukemia; Myeloproliferative Diseases

Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)
Status: Not yet recruiting Condition: Myeloproliferative Diseases

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Recruiting Condition: Leukemia

Ruxolitinib Prior to Transplant in Patients With Myelofibrosis
Status: Recruiting Condition: Primary Myelofibrosis; Post Polycythemia Vera Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis

Phase l/II Study of Ruxolitinib for Acute Leukemia
Status: Active, not recruiting Condition: Leukemia

Study of Ruxolitinib in Colorectal Cancer Patients
Status: Recruiting Condition: Metastatic Colorectal Cancer

Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL): Phase II
Status: Recruiting Condition: Leukemia

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
Status: Completed Condition: Myelofibrosis

A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
Status: Recruiting Condition: Primary Myelofibrosis

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Incyte Corp
ruxolitinib phosphate
TABLET;ORAL202192Nov 16, 2011RXYes<disabled><disabled>
Incyte Corp
ruxolitinib phosphate
TABLET;ORAL202192Nov 16, 2011RXNo<disabled><disabled>
Incyte Corp
ruxolitinib phosphate
TABLET;ORAL202192Nov 16, 2011RXYes8,829,013<disabled><disabled>
Incyte Corp
ruxolitinib phosphate
TABLET;ORAL202192Nov 16, 2011RXNo7,598,257<disabled>YY<disabled>
Incyte Corp
ruxolitinib phosphate
TABLET;ORAL202192Nov 16, 2011RXYes7,598,257<disabled>YY<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology